Compare Mesoblast Limited (MESO) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VICI Properties Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while VICI Properties Inc trades at $26.62 (market cap $29.55B). The key difference: VICI Properties Inc is far larger — about 13.6× Mesoblast Limited's market cap, and VICI Properties Inc pays a 6.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | VICI | |
|---|---|---|
Market Cap | $2.17B | $29.55B |
Sector | Technology | Real Estate |
52-Week High | $20.96 | $33.93 |
52-Week Low | $12.88 | $25.94 |
Enterprise Value | $2.17B | $46.77B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VICI Properties trades at $26.83, down 0.15% on the day, with technical indicators showing a neutral bias. The REIT maintains strong fundamentals with a 76.83% net income margin and consistent earnings beats in three of the last four quarters. Recent news highlights institutional buying interest and dividend sustainability discussions amid sector volatility.
VICI offers a compelling value proposition with a 6.7% dividend yield and 36% upside to the consensus price target of $30.00. Key risks include tenant concentration with Caesars/MGM accounting for 70% of rent and macroeconomic sensitivity. Wall Street remains bullish with 77% buy ratings supporting long-term income growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
